Arcellx Inc

Common Name
Arcellx
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
163
Ticker
ACLX
Exchange
NASDAQ/NGS
Description
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to h...

Financial Statements of Arcellx

Below are the financial statements of Arcellx, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in millions of USD202420232022
Collaboration revenue from related party
107.94a
110.32a
0a
Operating expenses
Research and development
-157.09a
-133.85a
-149.56a
General and administrative
-88.41a
-66.35a
-41.7a
Total operating expenses
-245.51a
-200.2a
-191.26a
Loss from operations
-137.57a
-89.88a
-191.26a
Other income (expense)
Interest and other income (expense)
33.32a
23.7a
4.3a
Interest expense
-1.03a
-3.84a
-1.72a
Total other income, net
32.29a
19.85a
2.58a
Loss before income taxes
-105.28a
-70.03a
-188.68a
Income tax expense
-2.07a
-0.66a
0a
Net loss
-107.35a
-70.69a
-188.68a

Verified Sources Behind Arcellx’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Arcellx’s data sources below and access millions more through our Disclosure Search.

a. Arcellx's 10-K 2024
Trace every data point back to Arcellx’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?